HOME > English Home > News Release 2007
News Release 2007
- September 28, 2007
- Kissei and Eisai sign a license agreement to develop and commercialize Glufast® a rapid-acting insulin secretagogue in China
- September 26, 2007
- Results of a Phase III Double-blinded Comparative Study of Silodosin (Brand name in Japan: Urief®) conducted in Europe
- July 23, 2007
- Kissei Entered into an Agreement with Nuon Therapeutics, Inc on Tranilast (Product Name: Rizaben®)
- June 12, 2007
- Kissei and Eisai sign a license agreement to develop and commercialize Glufast®, a rapid-acting insulin secretagogue in 10 ASEAN countries
- May 24, 2007
- Approval of an Additional Indication of Combination Therapy of Glufast® and
Alpha-glucosidase Inhibitor in Japan - April 24, 2007
- Construction of Joetsu Chemical Laboratory Completed
- April 23, 2007
- Application for an Additional Indication of Combination Therapy of Glufast® and Insulin Sensitizer in Japan
- January 17, 2007
- Results of US Phase III Double-blind Comparative Studies of Silodosin (Brand name in Japan: Urief®)
